IPCA Laboratories · NSE: IPCALAB · BSE: 524494

Q1 FY25 results · Apr–Jun 2024

IPCA Laboratories reported revenue from operations of ₹2,092.63 crore (up 31.8% from Q1 FY24) and net profit of ₹199.14 crore (up 21.4% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY25	Q1 FY24	YoY	Q4 FY24	QoQ
Revenue from operations	2,092.63	1,587.58	+31.8%	2,033.01	+2.9%
Other income	20.61	44.85	−54.0%	18.92	+8.9%
Total income	2,113.24	1,632.43	+29.5%	2,051.93	+3.0%
Profit before share of associates & JVs and tax	290.39	251.82	+15.3%	76.60	+279.1%
Share of profit/(loss) of associates & JVs	0.16	(2.11)		(1.58)
Net profit for the period	199.14	164.10	+21.4%	1.33	150x
Attributable to shareholders of the company	192.24	162.82	+18.1%	59.59	+222.6%
EPS, basic (₹)	7.58	6.42	+18.1%	2.35	+222.7%
Net margin (%)	9.5	10.3		0.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY25	Q1 FY24	YoY	Q4 FY24	QoQ
Revenue from operations	1,565.86	1,488.71	+5.2%	1,510.62	+3.7%
Other income	15.39	43.16	−64.3%	15.10	+1.9%
Total income	1,581.25	1,531.87	+3.2%	1,525.72	+3.6%
Profit before tax	287.89	249.58	+15.3%	127.30	+126.2%
Net profit for the period	204.13	166.58	+22.5%	64.76	+215.2%
EPS, basic (₹)	8.05	6.57	not comparable	2.55	not comparable
Net margin (%)	13.0	11.2		4.3

Consolidated

Filed with BSE: 14 Aug 2024, 14:50 IST
Board meeting: 13 Aug 2024
Period: 01 Apr 2024 to 30 Jun 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 14 Aug 2024, 14:50 IST
Board meeting: 13 Aug 2024
Period: 01 Apr 2024 to 30 Jun 2024
Review status: Unaudited
Source: XBRL filing on BSE